Aminoglycosides and carbenicillin are frequently co-administered to patients with serious gram-negative infections. Aminoglycosides are inactivated by carbenicillin in vitro, and a loss of antibacterial activity of both antibiotics results. Although these interactions are presumed to occur in vivo, previous studies have not used assay methodology that can distinguish inactivation occurring prior to and during microbiological assay from inactivation in vivo. To address this problem, we gave seven bilaterally nephrectomized mongrel dogs doses designed to achieve simultaneous therapeutic serum concentrations of aminoglycosides and carbenicillin. Serum samples were tested by radioimmunoassay on three occasions: immediately, to determine in vivo interactions, and at 24 h and 1 week to assess the time course of in vitro inactivation. In comparison with immediate radioimmunoassay, gentamicin and tobramycin concentrations decreased by 39 and 53%, respectively, when assayed at 24 h (P < 0.05) and by 75 and 82% when assayed at 7 days (P < 0.001). In contrast, amikacin concentrations were reduced by only 9 and 30% at 24 h and 7 days. Tobramycin concentrations were also determined by immediate microbiological assay and were found to be similar to those in samples stored for 24 h before radioimmunoassay. Immediate radioimmunoassay demonstrated that carbenicillin reduced in vivo serum half-lives of gentamicin and tobramycin by 40% (P < 0.05). The half-life of amikacin in vivo was not significantly altered. In the presence of carbenicillin, amikacin was the most stable aminoglycoside both in vivo and in vitro, and it is the aminoglycoside of choice in patients with renal failure who require this combination.
Aminoglycosides and carbenicillin are frequently co-administered to patients with serious gram-negative infections. Aminoglycosides are inactivated by carbenicillin in vitro, and a loss of antibacterial activity of both antibiotics results. Although these interactions are presumed to occur in vivo, previous studies have not used assay methodology that can distinguish inactivation occurring prior to and during microbiological assay from inactivation in vivo. To address this problem, we gave seven bilaterally nephrectomized mongrel dogs doses designed to achieve simultaneous therapeutic serum concentrations of aminoglycosides and carbenicillin. Serum samples were tested by radioimmunoassay on three occasions: immediately, to determine in vivo interactions, and at 24 h and 1 week to assess the time course of in vitro inactivation. In comparison with immediate radioimmunoassay, gentamicin and tobramycin concentrations decreased by 39 and 53%, respectively, when assayed at 24 h (P < 0.05) and by 75 and 82% when assayed at 7 days (P < 0.001). In contrast, amikacin concentrations were reduced by only 9 and 30% at 24 h and 7 days. Tobramycin concentrations were also determined by immediate microbiological assay and were found to be similar to those in samples stored for 24 h before radioimmunoassay. Immediate radioimmunoassay demonstrated that carbenicillin reduced in vivo serum half-lives of gentamicin and tobramycin by 40% (P < 0.05). The half-life of amikacin in vivo was not significantly altered. In the presence of carbenicillin, amikacin was the most stable aminoglycoside both in vivo and in vitro, and it is the aminoglycoside of choice in patients with renal failure who require this combination.
Concurrent carbenicillin and aminoglycoside therapy is frequently used in the treatment of gram-negative infections. This combination is synergistic in vitro against Pseudomonas (1, 6) . In 1971, McLaughlin and Reeves (7) demonstrated that gentamicin can be inactivated by carbenicillin in vitro. Subsequent studies have shown that both carbencillin and ticarcillin can inactivate aminoglycosides in vitro, with the rate of inactivation influenced by temperature, time, concentration, and the medium employed (5, 10, 11, 13) . This interaction causes inactivation of both antibiotics and loss of their antibacterial effect (10) .
Ervin and colleagues (3) reported that, after carbenicillin administration, gentamicin half-life decreased from a control mean of 46 h to 22 h in patients with end-stage renal disease. Davies and associates (2) studied patients with renal failure and found that the half-life of gentamicin decreased from a mean value of 54 h to 21 h after carbenicillin or ticarcillin therapy. However, neither of these studies used sampling and assay techniques which reliably differentiate inactivation occurring prior to assay from actual in vivo inactivation. kg, were bilaterally nephrectomized and divided into three groups. The first group (dogs 1, 2, and 3) received an intravenous bolus dose (7.5 mg/kg) and continuous infusion (4.5 mg/kg per h) of carbenicillin, via a volumetric infusion pump. After 2 h, they were given an intravenous bolus composed of gentamicin (2.0 mg/ kg), tobramycin (2.0 mg/kg), and amikacin (6.0 mg/ kg). Animals in the second group (dogs 4, 5, and 6) were each given an intravenous bolus of tobramycin (2.0 mg/kg) followed after 10 h by a bolus (7.5 mg/kg) and infusion (4.5 mg/kg per h) of carbenicillin. The last animal (dog 7) received only the intravenous mixture of gentamicin (2 mg/kg), tobramycin (2 mg/kg), and amikacin (6 mg/kg). All of these doses were chosen to achieve simultaneous therapeutic serum concentrations as follows: gentamicin, 10 ,ug/ml; tobramycin, 10 ug/ml; amikacin, 30 ug/ml; and carbenicillin, 200 to 300 ,ug/ml.
Blood sampling. Venous blood was drawn from a cannula in the right femoral vein at intervals of 15 min for the first 2 h after administration of either carbenicillin or aminoglycoside and then at intervals of 2 to 4 h for the next 24 to 48 h.
At each blood collection time, one-third of the sample (3 to 4 ml) was collected into a Vacutainer containing penicillinase (5,000 U/ml of sample), one-third was collected into a test tube containing cellulose phosphate powder (100 mg/ml of sample), and a third portion was collected and refrigerated. These procedures permitted the determination of aminoglycoside concentrations, carbenicillin concentrations, and the effect of storage, respectively.
Assays. Cellulose phosphate powder was added to samples to selectively bind aminoglycosides (12) . The procedure consisted of adding cellulose phosphate powder (ICN Biochemicals, Cleveland, Ohio), 100 mg/ ml, to blood. The mixture was blended on a Vortex mixer and centrifuged at 2,000 x g for 5 min. Carbenicillin concentrations in the supernatant were measured (as total antibiotic activity) by a modified agar well diffusion technique with the use of Bacillus subtilis spores. This microbiological procedure requires that assay plates be incubated for 12 h. Tobramycin activity in dogs 4, 5, and 6 was assayed by use of B. subtilis with penicillinase incorporated into the media (14) . Bioassay standard concentrations were 0.5, 1.0, 2.0, 4.0, and 8.0 pg/ml, with a coefficient of variation of 12% at 0.5 ,ug/ml and 8% at 8.0 ,ug/ml. With some samples, a high-pressure liquid chromatographic (HPLC) procedure was also used (4). A radioimmunoassay (RIA, Monitor Sciences, Newport Beach, Calif.) was used to determine aminoglycoside concentrations in all samples.
Assay specificity. The possibility that inactivated tobramycin could give a partial response by RIA or HPLC was assessed by spiking 50 ml of blank dog serum with tobramycin to a final concentration of 10 ,ug/ml. The sample was divided, and 500 ,Lg of carbenicillin per ml was added to one part. Both tobramycin and tobramycin-plus-carbenicillin samples were placed in a water bath at 37°C. Immediately after carbenicillin was added and again at 12 h, tobramycin concentrations were determined in triplicate by RIA, HPLC, and the B. subtilis bioassay.
Effects of penicillinase on carbenicillin inactivation. An in vitro study was performed to assess the role of penicillinase lysis of carbenicillin in tobramycin inactivation. The experiment was performed twice, in dog serum and in whole blood. A 200-ml tube of serum or blood was divided into four portions, and antibiotics were added as follows: tube 1, tobramycin (10 ,ug/ml) and penicillinase (500,000 U/ml); tube 2, the same as tube 1 plus carbenicillin (500 ,g/ml); tube 3, tobramycin and carbenicillin but no penicillinase; and tube 4, tobramycin (10 jug/ml) alone. All tubes were incubated at 37°C, and the contents were assayed for both tobramycin and carbenicillin at 0, 2, 4, 6, 8, 12, and 24 h. Tobramycin levels were measured by immediate RIA; carbenicillin levels, were measured by bioassay after inactivation of aminoglycoside with cellulose phosphate.
Effects of sample storage. Samples from dogs 1, 2, and 3 were assayed for aminoglycoside and carbenicillin immediately (10 mmn), after 24 h of refrigeration, and again at 7 days. Samples from dogs 4, 5, 6, and 7 were assayed immediately.
Analysis. Computer data fitting (8) and two-compartment linear modeling were used to describe the observed biexponential decline in aminoglycoside concentrations and to determine aminoglycoside serum half-lives. Statistical analysis was performed by use of the unpaired Student t test, with P < 0.05 considered significant.
RESULTS
The ability of cellulose phosphate to selectively bind and remove aminoglycosides was tested by adding therapeutic concentrations of gentamicin (10 jig/ml), tobramycin (10 ,ug/ml), and amikacin (30 ,ug/ml) to dog serum samples containing or not containing carbenicillin (500 ,ug/ml). Aminoglycoside and carbenicillin activity were determined by bioassay. Carbenicilhin was not affected by cellulose powder, since zone sizes were not significantly different between samples containing only carbenicillin (13.8 ± 0.8 mm) and samples containing carbenicillin and aminoglycosides plus cellulose powder (13.8 + 0.6 mm). No activity was noted in samples containing only aminoglycosides after treatment with cellulose powder.
Specificity of RIA and HPLC tobramycin assays. Tobramycin concentrations in the control sample free from carbenicillin were 9.89 + 0.13 ,ug/ml determined by RIA, 9.93 ± 0.09 ,ug/ ml by HPLC, and 9.84 ± 0.90 ,ug/ml by bioassay.
Immediately after carbenicillin addition, concentrations assayed were 9.94 ± 0.18 jig/ml by RIA, 9.96 ± 0.10 jig/ml by HPLC, and 6.63 ± 0.56 ,ug/ml by bioassay. These bioassay results were available after 12 h of incubation at 37°C.
Tobramycin concentrations determined after 12 h of incubation with carbenicillin were 6.63 ± 0.16 ,ug/ml by RIA, 6.17 + 0.30 ,ug/ml by HPLC, and 4.29 ± 0.54 ,ug/ml by bioassay. Since concentrations measured by RIA and HPLC at time zero closely approximated the known initial concentration, and because RIA and HPLC results determined after 12 h were similar to bioassay results read at 12 h (but prepared at time zero), it appears that there was significant loss during in vitro incubation, and that RIA, HPLC, and bioassay all measured only active tobramycin.
Penicillinase effects. As shown in Fig. 1 Effects of sample corection and storage.
The effects of carbenicilin on serum concentrations of gentamicin (Fig. 2), tobramycin (Fig. 3) , and amikacin (Fig. 4) were determined by assaying aminoglycoside concentrations 10 min after collection, after 24 h of refrigeration, and again after 7 days of refrigeration. When compared with the 10-min RIA results, gentamicin concentrations were reduced 39% and tobramycin concentrations were reduced 53% after 24 h of refrigeration (P < 0.05) and by 75 and 82% when assayed by RIA after 7 days (P < 0.001).
The rate of in vitro inactivation of gentamicin and tobramycin was nearly constant over the cinnical concentration range, because there was no significant difference in the slope of the 10-min, 24-h, or 7-day curves, and the standard deviation of percent decrease in aminoglycoside concentrations at each sample time was small.
In contrast to the marked inactivation of gentamicin and tobramycin, amikacin concentrations were reduced only 9% from the 10-min to the 24-h assay, and only a 30% decrease in amikacin activity occurred when samples were assayed again after 7 days of refrigeration (0.1 > P > 0.05).
Inactivation during microbiological assay incubation. Significant loss of tobramycin activity also occurred during the 12-h incubation of our microbiological assay, despite penicillinase treatment. Figure 5 shows the mean serum concentrations of tobramycin before and after carbenicillin administration. The solid line represents the mean immediate RIA concentrations, and the dashed line is the mean immediate microbiological assay concentration. In samples taken prior to carbenicillin administration, tobramycin concentrations determined by RIA and microbiological assay were nearly identical, with correlation coefficients above 0.95 in each of the three dogs. After carbenicillin administration, tobramycin concentrations determined by immediate RIA and HPLC were nearly identical (r = 0.95) and were significantly higher than microbiological assay results. Tobramycin concentrations determined by bioassay consistently averaged 65% of those determined by immediate RIA or HPLC. In vivo inactivation of gentamicin, tobramycin, and amikacin. The three aminoglycosides were administered as a simultaneous mixture to dogs 1, 2, 3, and 7 so that their comparative in vivo disposition could be assessed under identical physiological conditions. Table 1 compares the effect of carbenicillin on the in vivo serum half-lives of gentamicin, tobramycin, and amikacin. In the control animal, the in vivo serum half-lives of these three aminoglycosides were 30. 4 carbenicillin (28.6 h). The in vivo effects of carbenicillin on the halflife of tobramycin alone were also assessed in dogs 4, 5, and 6. The mean half-life was significantly reduced from 27.8 ± 1.2 h before to 16.9 ± 1.8 h after carbenicillin administration (P < 0.01). This reduction was nearly identical to that observed when dogs 1, 2, and 3 were compared with the control.
DISCUSSION
Carbenicillin and an aminoglycoside are frequently given to patients with suspected or proven gram-negative infections. Although this combination has been shown to be synergistic against P. aeruginosa, in vitro inactivation of aminoglycosides has been reported. This interaction does not contradict the reports of synergism, because in most patients with normal renal function, the antibacterial effects of aminoglycosides and carbenicillin are thought to occur prior to any significant loss of activity. However, Murillo and associates have -recently observed ticarcillin-associated reductions in gentamicin concentrations in granulocytopenic patients with normal serum creatinines (9) . In contrast to the few reports of the interaction in patients with normal renal function, there are numerous reports of interactions in patients with renal failure. These are presumably facilitated by high concentrations of these antimicrobial agents, in contact for extended periods of time (10) . However, none ofthese studies used specific sampling and assay methodologies which would reliably differentiate in vitro from in vivo interactions.
In this study, we distinguished in vitro from in vivo inactivation of aminoglycosides by carbenicillin, as is best illustrated in Fig. 5 . The in vitro inactivation was shown by comparison of aminoglycoside concentrations quantitated by immediate RIA with those determined by either immediate microbiological assay or delayed RIA.
As shown by immediate RIA, true in vivo interaction was observed and quantitated in both groups of animals. In the first group, gentamicin and tobramycin half-lives were reduced by approximately 40% as compared with the control. In vivo tobramycin serum half-life was similarly reduced after carbenicillin administration in the second group. However, these reductions were less than those reported by Riff (11) or Davies (2) , who employed microbiological assays exclusively.
Since most previous studies of this interaction have used the bioassay, inactivation reported as in vivo may have been an in vitro problem or a combination of in vitro and in vivo inactivation. We have demonstrated that the RIA and HPLC procedures measure biologically active tobramycin, as does the microbiological procedure if a correction is made for the inactivation that occurs over the time required for bioassay incubation. However, we point out that calculation of a correction factor for bioassay is not possible, since the rate of reaction is also dependent on the carbenicillin concentration in the blood sample, and time between sampling and application to bioassay plates is usually not known. We have also shown that in vitro destruction of carbenicillin dramatically slows the rate of the inactivation, but we were somewhat surprised that it did not completely stop it. This conclusion was also apparent from our in vivo dog experiments. It was of great interest that whole blood apparently protects the carbenicillin in some fashion, as the reaction proceeds even more quickly in this medium. Potential explanations for this accelerated effect include intracellular carbenicil-'in shielded from lysis by the penicillinase, tobramycin sequestration inside or binding to erythrocytes, resulting in loss of activity, or possibly some component of erythrocytes acting as a catalyst for this reaction.
Amikacin was the most stable aminoglycoside in the presence of carbenicillin, both in vitro and in vivo. Concentrations were reduced by only 9 and 30% in vitro when assayed after 24 h and 7 days of refrigeration, over the carbenicillin/amikacin concentration range of 5:1 to 25:1. These findings are in agreement with in vitro data previously reported (5, 10), which showed amikacin to be the most stable. Also, because amikacin concentrations determined by delayed RIA and microbiological assay correlated well with immediate RIA results (r = 0.98), the bioassay is useful here, and the need for rapid assay is less acute than with tobramycin or gentamicin.
In contrast to gentamicin and tobramycin, in vivo amikacin half-life in the carbenicillin- The significance of these findings for patients with normal renal function deserves further investigation, and such studies must employ immediate RIA to differentiate in vitro from in vivo inactivation.
Finally, the therapeutic significance of our results is that, if tobramycin or gentamicin dosage increases are based on serum concentrations determined by microbiological assay, inactivation due to incubation will yield a falsely low value, which could mislead and result in an increased dosage. Actual in vivo levels may rise into the toxic range as a result. The significance of these findings for patients with normal renal function deserves further investigation, and such studies must employ immediate RIA to differentiate in vitro from in vivo inactivation.
